Vaxart, Inc. announced that the complete clinical dataset from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine will be highlighted in an oral presentation at the World Vaccine Congress (WVC), taking place from April 2-5, 2018 in Washington, D.C.
“We are delighted to present the full dataset from our Phase 2 Challenge study, as the results demonstrate a statistically significant reduction in the rate of influenza infection, support our tablet vaccine approach, and highlight its potential to provide superior protection against influenza,” said Sean Tucker, Ph.D., founder and chief scientific officer of Vaxart. “In addition, our studies performed in ferrets showed that the oral vaccine approach may improve protection against influenza strains that do not match the vaccine strain. With the limitations of standard of care injectable vaccines, there’s a strong desire in the scientific community to find innovative methods to develop cross-protective influenza vaccines.”
Details of the presentation are as follows:
|
Presentation Title: |
Comparisons between QIV and Vaxart’s oral vaccine for protection against influenza challenge in humans | |
|
Date & Time: |
Wednesday, April 4, 2018 at 12:55 PM ET | |
|
Authors: |
Sean Tucker, et al. | |
|
Session: |
Universal and Pandemic Influenza Vaccines |
The Phase 2 study was completed with support from the Biomedical Advanced Research and Development Authority (BARDA). Vaxart received a $13.9 million contract from BARDA in September 2015 to support the advanced development of more effective influenza vaccines to ultimately improve seasonal and pandemic influenza preparedness.
The project has been funded in whole or in part with federal funds from the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. HHSO100201500034C.
All recent presentations are available on the Vaxart website under Newsroom at www.vaxart.com.
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform. Vaxart’s vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines, and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). Vaxart is also developing several small-molecule antiviral drug candidates, including teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV types 6 and 11. For more information, please visit www.vaxart.com.
